Plovdiv

• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit … Recruiting
  2023-504835-42-00 4 2024-02-29 Heart Failure (Heart Failure with Reduced Ejection Fraction)
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o … Recruiting
  2022-502193-16-00 5 2023-11-14 Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting
  2022-500699-76-00 5 2023-05-18 Active Systemic Lupus Erythematosus (SLE)
• A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic St … Recruiting
  2023-510548-19-00 4 2023-03-02 Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
• A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin rece … Recruiting
  2023-504885-50-00 5 2022-11-07 Treatment of children with chronic kidney disease and proteinuria
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi … Recruiting
  2023-504599-10-00 4 2022-03-29 Chronic lymphocytic leukemia recurrent
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment Recruiting
  2024-516291-16-00 3 2021-10-26 Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i … Recruiting
  2023-504417-67-00 6 2020-12-22 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
• Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
  2023-509179-18-00 1 2019-08-13 Castration Resistant Prostate Cancer (CRPC)
• A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting
  2024-512701-11-00 4 2018-08-29 Systemic Juvenile Idiopathic Arthritis (sJIA)

Showing 169–192 of 408 trials